Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amivantamab + hyaluronidase-lpuj + lazertinib
- Development stage
- Unknown
- Lead developer
- Yuhan
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral, Subcutaneous
01
Overview
Rybrevant FASPRO + Lazcluze is a combination regimen consisting of Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), a subcutaneous bispecific antibody targeting EGFR and MET co-formulated with recombinant human hyaluronidase PH20, and Lazcluze (lazertinib), an oral third-generation EGFR tyrosine kinase inhibitor. Developed by Johnson & Johnson, this chemotherapy-free combination is approved by the FDA as a first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations. The subcutaneous formulation significantly reduces administration time from hours (for the intravenous form) to approximately five minutes and lowers the rate of administration-related reactions.
- Brand names
- Rybrevant FASPRO + Lazcluze
- Other names
- amivantamab + hyaluronidase + lazertinibsubcutaneous amivantamab and hyaluronidase-lpuj plus lazertinibsubcutaneous amivantamab plus lazertinib
02
Targets
EGFR (Epidermal growth factor receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on amivantamab + hyaluronidase-lpuj + lazertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amivantamab + hyaluronidase-lpuj + lazertinib.